Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Merck Sharp & Dohme LLC
Pfizer